Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Opportunities to Optimize Cancer Policies Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Dec
24
Today In Oncology
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers
Deb Schrag Elected 2027–2028 ASCO President
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo